NECTA DRUG DEVELOPMENT
  • 2026 Program
  • Registration
  • Sponsors
  • Recordings
  • Previous Programs
    • 2025 Program
    • 2024 Program
    • 2023 Program
    • 2022 Program
    • 2021 Program
    • 2020 Program
    • 2019 Program
    • 2018 Program
    • 2017 Program

2018 Program

​
PROGRAM DRUG DEVELOPMENT MEETING MARCH 22-23, 2018
Day 1 

830 Welcome – A/Prof Anthony Joshua
835 Opening Address – Dr David Currow
 
Session 1 - Phase 1 The Next Generation - Moderator - Dr Lisa Horvath (Lifehouse)
 
845 -930          Prof Johann De Bono – Where next in Phase 1?
930-945           Discussion
945-1015         A/Prof David Ziegler – What’s new in Paediatric phase 1? The national WGS, RNA-Seq, avatar effort in paediatric tumours
​1015-1030      Discussion
1030-11         A/Prof Catriona McNeil – NSW Perspectives on Phase 1 – A view from the coal-face
 
11-1130           Morning Tea
 
1130-12          Prof Jayesh Desai – VCCC – Pushing the Boundaries in Phase 1 Trials
12-1230          Dr Alex Menzies - Integrating research into Early phase trials in Melanoma
1230-1            Prof Sabe Sabesan  - Clinical trial access to rural, regional and rare cancer patients using telehealth
 
1-2                  Lunch
 
Session 2 – Immuno-Oncology Looking over the Horizon - Moderator - Dr Charlotte Lemech (Scientia)
 
2-245             Prof Thomas Gajewski – The Next Generation of Immuno-Oncology
245-3             Discussion
3-330             Prof Chris Goodnow – Germline influences on Responses to Immuno-Oncology
 
330-4               Afternoon Tea and Posters

4-430              Prof Kerrie MacDonald – Immuno-Oncology in GBM
430-5              Prof Philip Darcy – CAR-T cell therapies in Cancer 
5-530              Prof David Thomas - Genomics and Immuno-Genomics in Early Phase Trials
 
630               Faculty Dinner
 
Day 2  Pipeline Presentations from Pharma (Indicative Only) - Moderator - Dr Amy Prawira (TKCC)
830-9         Macrogenics
9-930         MSD
930-10       BMS
10-1030     Morning Tea
1030-11     AstraZeneca/ MedImmune
11-1130       Amgen
1130-1230   Lunch 
1230-1         Janssen
1-130          Roche/Genentech
130-2        Novartis
 
    
  • 2026 Program
  • Registration
  • Sponsors
  • Recordings
  • Previous Programs
    • 2025 Program
    • 2024 Program
    • 2023 Program
    • 2022 Program
    • 2021 Program
    • 2020 Program
    • 2019 Program
    • 2018 Program
    • 2017 Program